NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma has successfully completed enrollment for the chronic cohort of its Phase 1b/2a clinical trial of NVG-291, aimed at treating spinal cord injuries, marking a significant milestone. With Institutional Review Board approval for protocol amendments, the company is now moving forward with the subacute cohort screening, aiming to enhance the recruitment process. This progress sets the stage for a pivotal year, as NervGen continues its commitment to bringing NVG-291 to individuals living with spinal cord injuries.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.